Evidence map›Paper›PMID 32774834›Full record

ArticleHepatic oncology2020

Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery.

Elisabetta Goio, Luca Ielasi, Francesca Benevento, Matteo Renzulli, Francesco Tovoli

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Neoadjuvant treatment strategies for hepatocellular carcinoma.World journal of gastrointestinal surgery · 2021
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Elisabetta GoioDepartment of Medical & Surgical Sciences, Unit of Internal Medicine, University of Bologna, Bologna, 40138, Italy.
Luca IelasiDepartment of Medical & Surgical Sciences, Unit of Internal Medicine, University of Bologna, Bologna, 40138, Italy.
Francesca BeneventoDepartment of Medical & Surgical Sciences, Unit of Internal Medicine, University of Bologna, Bologna, 40138, Italy.
Matteo RenzulliUnit of Radiology, S Orsola-Malpighi Bologna Authority Hospital, Bologna, 40138, Italy.ORCID https://orcid.org/0000-0002-1311-5670
Francesco TovoliDepartment of Medical & Surgical Sciences, Unit of Internal Medicine, University of Bologna, Bologna, 40138, Italy.ORCID https://orcid.org/0000-0002-8350-1155
University of Bologna · ITIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe therapeutic scenario of systemic treatments for hepatocellular carcinoma (HCC) is rapidly changing. There is much interest in the possibility of combining new therapies with surgery, but clinical data is lacking. We aimed to provide an example of such integration. PATIENTS &

methodsWe report a patient with metastatic HCC who received regorafenib in the setting of the RESORCE trial.

resultsA brilliant response led to a tumor downstaging and a subsequent adrenal metastasectomy with radical intent.

conclusionsNew agents will change the therapeutic perspectives in advanced HCC and lead to a higher rate of objective responses, with possibilities of associating systemic therapy and surgery. Thus, the management of HCC will require more and more of an integrated, multidisciplinary and personalized approach.

Indexed as

atezolizumabhepatocellular carcinomaimmune checkpoint inhibitorsneoadjuvant therapynivolumabnonalcoholic steatohepatitispembrolizumabregorafenibsorafenib

Identifiers

PMID32774834
PMCPMC7399611
OpenAlexW3038868873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.